Manickam Rangaraju

470 total citations
16 papers, 356 citations indexed

About

Manickam Rangaraju is a scholar working on Epidemiology, Microbiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Manickam Rangaraju has authored 16 papers receiving a total of 356 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Epidemiology, 5 papers in Microbiology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Manickam Rangaraju's work include Pneumonia and Respiratory Infections (12 papers), Respiratory viral infections research (5 papers) and Bacterial Infections and Vaccines (5 papers). Manickam Rangaraju is often cited by papers focused on Pneumonia and Respiratory Infections (12 papers), Respiratory viral infections research (5 papers) and Bacterial Infections and Vaccines (5 papers). Manickam Rangaraju collaborates with scholars based in France, United States and Sweden. Manickam Rangaraju's co-authors include Bruno Leroy, Antoine Tarral, Henri Merdjan, Kees-Peter de Roos, Michel Aubier, Lars Hagberg, Roomi Nusrat, E. Ruuth, Arturo Fraile Torres and A M Leak and has published in prestigious journals such as CHEST Journal, Journal of Medicinal Chemistry and Journal of Hepatology.

In The Last Decade

Manickam Rangaraju

15 papers receiving 332 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Manickam Rangaraju France 9 270 116 115 94 47 16 356
L. Aguilar Spain 12 260 1.0× 137 1.2× 205 1.8× 35 0.4× 113 2.4× 39 413
Jacques Dubois Canada 13 225 0.8× 127 1.1× 119 1.0× 34 0.4× 91 1.9× 27 447
Rick Player United States 6 273 1.0× 108 0.9× 164 1.4× 51 0.5× 53 1.1× 8 400
Partha Bagchi United States 8 118 0.4× 85 0.7× 136 1.2× 54 0.6× 185 3.9× 10 402
Cheryl Volling Canada 6 128 0.5× 101 0.9× 39 0.3× 65 0.7× 47 1.0× 8 323
H. Carsenti-Etesse France 11 215 0.8× 44 0.4× 56 0.5× 32 0.3× 62 1.3× 22 349
Roomi Nusrat United States 9 120 0.4× 45 0.4× 57 0.5× 36 0.4× 36 0.8× 13 175
W Huck United States 10 252 0.9× 42 0.4× 68 0.6× 34 0.4× 71 1.5× 13 372
R Hullmann Germany 5 159 0.6× 79 0.7× 243 2.1× 33 0.4× 62 1.3× 10 407
Maria Crain United States 7 154 0.6× 43 0.4× 57 0.5× 31 0.3× 62 1.3× 12 293

Countries citing papers authored by Manickam Rangaraju

Since Specialization
Citations

This map shows the geographic impact of Manickam Rangaraju's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manickam Rangaraju with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manickam Rangaraju more than expected).

Fields of papers citing papers by Manickam Rangaraju

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manickam Rangaraju. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manickam Rangaraju. The network helps show where Manickam Rangaraju may publish in the future.

Co-authorship network of co-authors of Manickam Rangaraju

This figure shows the co-authorship network connecting the top 25 collaborators of Manickam Rangaraju. A scholar is included among the top collaborators of Manickam Rangaraju based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manickam Rangaraju. Manickam Rangaraju is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Hammond, Sarah P., et al.. (2024). A Multicenter Assessment of the Outcomes and Toxicities of Foscarnet for Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex in Immunocompromised Patients. Open Forum Infectious Diseases. 11(3). ofae046–ofae046. 6 indexed citations
2.
Rangaraju, Manickam, et al.. (2024). 642 The role and use of digital simulation in plastic surgery training: A Systematic Review. British journal of surgery. 111(Supplement_6).
3.
Birkmann, Alexander, et al.. (2022). Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Treatment Option for Acyclovir-Resistant Herpes Simplex Virus Infections. Journal of Medicinal Chemistry. 65(20). 13614–13628. 25 indexed citations
4.
Jambrecina, Alen, Thomas Berg, Florian van Bömmel, et al.. (2019). FRI-199-First in Human, single ascending dose clinical trial of AIC649 in patients with chronic hepatitis. Journal of Hepatology. 70(1). e478–e479. 9 indexed citations
5.
6.
Carbon, C, Lars Hagberg, Charles Fogarty, et al.. (2006). Clinical and bacteriologic efficacy of telithromycin in patients with bacteremic community-acquired pneumonia. Respiratory Medicine. 100(4). 577–585. 8 indexed citations
7.
Fogarty, Charles, et al.. (2005). Telithromycin in the treatment of pneumococcal community-acquired respiratory tract infections: a review. International Journal of Infectious Diseases. 10(2). 136–147. 6 indexed citations
8.
Fogarty, Charles, Marcus Zervos, Guy Tellier, et al.. (2005). Telithromycin for the treatment of acute exacerbations of chronic bronchitis. International Journal of Clinical Practice. 59(3). 296–305. 5 indexed citations
9.
Roos, Kees-Peter de, et al.. (2005). Bacteriological efficacy of 5-day therapy with telithromycin in acute maxillary sinusitis. International Journal of Antimicrobial Agents. 25(3). 237–246. 2 indexed citations
10.
11.
Fogarty, Charles, et al.. (2004). Efficacy of oral telithromycin in community-acquired pneumonia caused by resistant Streptococcus pneumoniae. Journal of Infection. 51(3). 201–205. 2 indexed citations
12.
Low, Donald E., D. Felmingham, Susan J. Brown, Manickam Rangaraju, & Roomi Nusrat. (2004). Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections. Journal of Infection. 49(2). 115–125. 15 indexed citations
13.
Roos, Kees-Peter de, et al.. (2004). Clinical and bacteriological efficacy of 5-day telithromycin in acute maxillary sinusitis: a pooled analysis. Journal of Infection. 50(3). 210–220. 16 indexed citations
14.
Aubier, Michel, et al.. (2002). Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis. Respiratory Medicine. 96(11). 862–871. 59 indexed citations
15.
16.
Roos, Kees-Peter de, et al.. (2002). Efficacy and Tolerability of Once-Daily Therapy with Telithromycin for 5 or 10 Days for the Treatment of Acute Maxillary Sinusitis. Chemotherapy. 48(2). 100–108. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by L. Aguilar Breakdown of academic impact, for papers by Jacques Dubois Breakdown of academic impact, for papers by Rick Player Breakdown of academic impact, for papers by Partha Bagchi Breakdown of academic impact, for papers by Cheryl Volling Breakdown of academic impact, for papers by H. Carsenti-Etesse Breakdown of academic impact, for papers by Roomi Nusrat Breakdown of academic impact, for papers by W Huck Breakdown of academic impact, for papers by R Hullmann Breakdown of academic impact, for papers by Maria Crain
Rankless by CCL
2026